CSL Limited (CMXHF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Paul F. McKenzie Ph.D. | MD, CEO & Executive Director | 4.37M | -- | 1966 |
| Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI | Chief Financial Officer | 2.05M | -- | 1965 |
| Mr. Andy Schmeltz | Executive Vice President of CSL Behring | 1.48M | -- | 1972 |
| Chris Cooper | Head of Investor Relations | -- | -- | -- |
| Mr. Gregory Boss B.S., BS(Hons), J.D. | Executive VP of Legal & General Counsel | 1.1M | -- | 1961 |
| Ms. Roanne Parry | Chief Human Resources Officer | -- | -- | 1973 |
CSL Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 32,698
Description
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Corporate Governance
Upcoming Events
February 10, 2025 at 9:11 PM UTC
CSL Limited Earnings Date
Recent Events
March 10, 2025 at 12:00 AM UTC
Ex-Dividend Date
April 4, 2014 at 12:00 AM UTC
Dividend Date